Top Page
Impedimed Limited
(Sydney:IPD)
Impedimed Limited (IPD) vs. iShares MSCI Australia ETF (EWA)
Impedimed Limited Business Overview & Revenue Model
Impedimed Limited Earnings Call Summary
Impedimed Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.54M | 12.72M | 10.32M | 11.34M | 10.57M | 8.41M |
| Gross Profit | 10.14M | 10.97M | 9.01M | -13.65M | -13.35M | -12.20M |
| EBITDA | -21.08M | -17.55M | -22.05M | -20.49M | -18.65M | -20.70M |
| Net Income | -21.22M | -23.24M | -19.79M | -20.52M | -19.87M | -20.71M |
Balance Sheet | ||||||
| Total Assets | 39.19M | 41.66M | 46.99M | 68.74M | 58.70M | 34.20M |
| Cash, Cash Equivalents and Short-Term Investments | 17.69M | 22.18M | 24.63M | 45.71M | 40.73M | 19.68M |
| Total Debt | 1.05M | 14.49M | 1.14M | 1.45M | 170.00K | 474.00K |
| Total Liabilities | 6.87M | 21.16M | 6.24M | 7.86M | 7.66M | 8.69M |
| Stockholders Equity | 32.32M | 20.50M | 40.74M | 60.88M | 51.04M | 25.51M |
Cash Flow | ||||||
| Free Cash Flow | -19.72M | -15.63M | -20.89M | -24.09M | -20.89M | -15.71M |
| Operating Cash Flow | -18.29M | -14.64M | -17.79M | -18.05M | -15.66M | -13.26M |
| Investing Cash Flow | -2.02M | -989.00K | -3.10M | -6.04M | -5.22M | -2.46M |
| Financing Cash Flow | -462.00K | 13.64M | -481.00K | 27.93M | 39.92M | 16.47M |
Impedimed Limited Technical Analysis
Impedimed Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$70.02M | -5.38 | -31.98% | ― | 34.20% | -23.90% | |
50 Neutral | AU$61.51M | -46.38 | -6.35% | ― | 2.23% | -263.16% | |
48 Neutral | $77.42M | ― | -74.00% | ― | 23.31% | -17.35% | |
44 Neutral | AU$171.94M | -16.13 | -70.55% | ― | ― | -257.32% | |
43 Neutral | AU$40.59M | ― | -44.16% | ― | 25.47% | 14.08% | |
41 Neutral | AU$58.77M | ― | -128.19% | ― | -14.25% | -22.83% |
Impedimed Limited Corporate Events
ImpediMed Limited has announced that additional U.S. insurers have initiated coverage for the use of bioimpedance spectroscopy (BIS) for lymphoedema assessment, expanding reimbursement to over 314 million covered lives. This development marks a significant milestone in providing broader access to early detection and monitoring of lymphoedema, enhancing patient care and potentially reducing long-term complications. The expanded insurance coverage is expected to boost the commercial viability of ImpediMed’s SOZO platform, facilitating its adoption and supporting the company’s mission to improve health outcomes for cancer patients at risk of lymphoedema.
ImpediMed Limited has received a $1.2 million R&D tax incentive refund for its research and development activities, which bolsters its cash position and supports the ongoing development and commercialization of its SOZO platform. The company’s cash balance at the end of Q2 FY26 was $23.0 million, indicating a strong financial position that aids its growth in the digital health market, particularly in cancer-related lymphoedema.
ImpediMed Limited held its Annual General Meeting where all proposed resolutions were passed, including the remuneration report and the re-election of board members Ms. Christine Emmanuel-Donnelly and Mr. McGregor Grant. The successful passage of these resolutions indicates strong shareholder support and stability in the company’s governance, which could positively impact its strategic direction and stakeholder confidence.
ImpediMed Limited announced the CEO’s presentation for the 2025 Annual General Meeting, highlighting the company’s commitment to advancing healthcare standards through its proprietary technology. This announcement underscores ImpediMed’s strategic focus on enhancing its market position by setting new benchmarks in patient care, potentially impacting stakeholders by reinforcing the company’s leadership in medical technology innovation.
Impedimed Limited’s 2025 Annual General Meeting highlighted significant achievements, including a 23% revenue growth and increased payor coverage in 26 states, which is expected to boost BCRL sales. The company is strategically investing in sales capabilities and refining processes to enhance SOZO device utilization. The SOZO digital health platform, with FDA-cleared applications, presents substantial opportunities in heart failure and body composition markets, valued at $1.1 billion and $600 million respectively. The board supports exploring collaborations and acquisitions to maximize the platform’s value, while cost resizing efforts aim to secure future success.
ImpediMed Limited announced a change in the director’s interest notice, revealing that Mr. Andrew Grant, a director, has increased his holdings in the company by acquiring 98,347 ordinary shares. This acquisition was made in lieu of 15% of his director fees for the quarter ended 30 September 2025, reflecting a strategic move to align interests with the company’s performance. This development may indicate confidence in the company’s future prospects and could potentially impact stakeholder perceptions positively.
ImpediMed Limited announced a change in the director’s interest, with Ms. Christine Emmanuel-Donnelly acquiring additional ordinary shares through IDEAHL Pty Ltd. The acquisition was made in lieu of 15% of director fees for the quarter ended 30 September 2025, reflecting a strategic move to align director compensation with company performance. This change in shareholding may impact the company’s governance and stakeholder confidence by demonstrating the director’s commitment to the company’s growth and success.
ImpediMed Limited has announced a change in the interests of its director, Ms. Janelle Delaney, who has acquired an additional 98,347 ordinary shares, bringing her direct holdings to 1,881,481 shares. This acquisition was made through the issuance of shares in lieu of 15% of her director fees for the quarter ended September 30, 2025. The announcement reflects the company’s ongoing practices in managing director compensation and may have implications for shareholder perceptions of director alignment with company performance.
Impedimed Limited announced a change in the director’s interest, with Fiona Bones acquiring 98,347 ordinary shares, increasing her total holdings to 1,872,746 shares. This acquisition was part of an issue of shares in lieu of 15% of director fees for the quarter ended 30 September 2025, indicating a strategic move to align director interests with company performance.
Impedimed Limited announced the issuance of 438,223 ordinary fully paid shares to its non-executive directors as part of the Non-Executive Director Share Plan, covering 30% of director fees for the quarter ending September 30, 2025. This move reflects the company’s ongoing commitment to aligning the interests of its directors with those of its shareholders, potentially impacting its market perception and stakeholder confidence positively.
Impedimed Limited announced the issuance of 843,574 fully paid ordinary shares to an executive as part of their remuneration under the Executive Share Plan for the quarter ended September 30, 2025. This move reflects the company’s strategic approach to executive compensation, potentially impacting its financial operations and signaling a commitment to aligning executive interests with company performance.
ImpediMed Limited has released an investor presentation detailing its Q1 FY26 results, which will be delivered to investors and analysts. This announcement is part of the company’s ongoing efforts to maintain transparency with stakeholders and provide insights into its financial performance and strategic direction.
ImpediMed Limited reported a record revenue of A$3.6 million for the first quarter of FY26, despite challenges such as a stronger Australian dollar and delays in hospital approvals. The company is expanding its market presence with over 600 SOZO units installed in leading US hospitals and new system agreements providing access to over 700 hospitals. The launch of SOZO Pro, the only FDA-cleared BIS device for patients with cardiac implantable devices, is expected to drive scalable growth. Despite a decrease in Total Contracted Value compared to the previous quarter, the company saw a 9% revenue increase and maintained a low churn rate, indicating strong market demand and customer retention.
ImpediMed Limited has announced the upcoming release of its Q1 FY26 Quarterly Cash Flow Report and the launch of the ImpediMed Investor Hub. The Investor Hub is designed to improve communication and engagement with investors by providing a centralized platform for accessing company updates, ASX announcements, and strategic insights. This initiative aims to offer investors a deeper understanding of ImpediMed’s products and growth opportunities, potentially enhancing stakeholder engagement and market positioning.
ImpediMed Limited announced a correction to its 2025 Remuneration Report, clarifying that the Board Chair’s fee will be paid 85% in cash and 15% in equity, aligning with the payment structure for other Non-executive Directors. This adjustment reflects the company’s commitment to transparency and consistency in its remuneration practices, which may impact stakeholder perceptions and corporate governance standards.
ImpediMed Limited has announced the details for its upcoming Annual General Meeting, which will be held online on November 18, 2025. The company has provided an online meeting guide to assist shareholders in attending and voting during the meeting, emphasizing the need for compatible browsers and necessary identification information.
Impedimed Limited announced the cessation of certain securities, specifically the lapse of 1,181,000 options and 7,556,058 performance rights due to unmet conditions. This announcement may impact the company’s financial structure and could influence investor perceptions regarding the company’s operational and strategic execution.
Impedimed Limited announced the issuance of 17,250,000 unquoted equity securities under an employee incentive scheme, which are not intended to be quoted on the ASX. This move could potentially strengthen the company’s employee engagement and retention strategies, while also impacting its financial structure and market positioning.
ImpediMed Limited announced that a major US health insurer has issued positive coverage for bioimpedance spectroscopy (BIS) under CPT Code 93702, recognizing it as medically necessary for lymphedema assessment. This development significantly expands insurance coverage for ImpediMed’s SOZO® Digital Health Platform, now covering over 301 million lives and 86% of the US population. The decision is expected to enhance the commercial viability of SOZO, allowing for earlier detection and better management of lymphedema, thus improving the quality of life for breast cancer survivors. This expanded coverage is a crucial step towards proactive health management and aligns with the insurer’s mission to provide high-quality care.
ImpediMed Limited has announced that its 2025 Annual General Meeting will be held on November 18, 2025. The company is also accepting nominations for director positions, with a deadline for submissions set for September 26, 2025. This announcement is significant for stakeholders as it outlines key governance activities and timelines, potentially impacting the company’s strategic direction and leadership.